Stereotaxis, Inc. (NYSE:STXS) Q4 2024 – Earnings Conference Call March 3, 2025 8:30 AM ET
Company Participants
David Fischel – Chairman and CEO
Kimberly Peery – CFO
Conference Call Participants
Frank Takkinen – Lake Street Capital Markets
Adam Maeder – Piper Sandler
Jason Wittes – ROTH Capital Partners
Operator
Good morning. Thank you for joining us for Stereotaxis Fourth Quarter and Full Year 2024 Earnings Conference Call. Certain statements during the conference call and question and answer period to follow may relate to future events, expectations, and as such, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the company in the future to be materially different from the statements that the company’s executives may make today. These risks are described in detail in our public filings with the Securities and Exchange Commission, including our latest periodic report on Form 10K or 10Q.
We assume no duty to update these statements. At this time, all participants has been placed on listen-only mode. The floor will be opened for questions and comments following the presentation.
As a reminder, today’s call is being recorded. It is now my pleasure to turn the floor over to your host, David Fischel, Chairman and CEO of Stereotaxis.
David Fischel
Thank you, operator, and good morning, everyone. It’s an exciting time at Stereotaxis. We are making significant broad-based progress in establishing the attractive foundations on which to grow a substantial company. In tandem with our quarterly results, this morning we announced in separate press releases two significant milestones with FDA submissions made for key catheter innovations. Stereotaxis is in the midst of a major strategic transformation.
I’ll discuss our
Read the full article here